Nervous Disorder TRIZ Cases

An opioid agonist linked to a water-soluble oligomer slows central nervous system entry, reducing abuse potential and peripheral side effects.

Human immature dental pulp stem cells cross the blood-brain barrier to deliver sustained brain-derived neurotrophic factor secretion.

Glycolysis inhibitors restrict glucose utilization to promote wild-type mtDNA replication, reversing disease progression by reducing mutant load.

Bile salt formulations improve oral cannabidiol bioavailability, achieving stable plasma levels while minimizing liver enzyme elevations.

A fused ring compound targets 5-HT3 receptors and monoamine transporters to treat central nervous system disorders.

Lactobacillus plantarum PS128 reduces serum corticosterone to treat stress-induced disorders.

Host cell expression solves extraction difficulties to yield high-purity keratin BD-3 with antipyretic and antiviral effects.

A differentiation method uses a MEK inhibitor to produce midbrain dopaminergic neurons with high purity and concentration.

Replacing glucocorticoids with proguanil eliminates adverse side effects while maintaining anti-inflammatory efficacy and providing neuroprotective benefits.

Segmentation and local quality principles guide antibody design to resolve diagnostic specificity bottlenecks in tauopathy treatment.

Administering a VEGFR3 agonist increases meningeal lymphatic vessel diameter, improving amyloid-beta clearance efficiency and reducing plaque accumulation.

An oral dual-enzyme composition converts toxic acetaldehyde to acetate, preventing liver toxicity from pain relievers.

A scaffold-free nerve conduit uses aligned Schwann cells to accelerate nerve regeneration and improve functional recovery.

Amyloid core mimic peptides bind Aβ and IAPP with nanomolar affinity to redirect assembly into non-toxic co-assemblies.

Combinatorial therapies delay motor neuron degeneration and paralysis by addressing multiple pathogenic mechanisms simultaneously.

Segmentation of aminoacyl-tRNA synthetases reveals resectins with extracellular signaling, uncovering masked therapeutic targets.

A liposome vaccine delivers phosphorylated tau peptides to generate antibodies that block seeding activity.

Purified cannabidiol reduces tonic and focal seizure frequency in patients with autosomal dominant nocturnal frontal lobe epilepsy.

Anti-PD-L1 antibodies with ADCC activity block PD-L1 and PD-1 interactions to enhance T-cell function and treat cancer.

A binding protein comprising the extracellular domain of CD39 targets activated platelets to reduce neuroinflammation.

Selective PTEN antagonist peptides enhance axon regeneration in spinal cord injury models while avoiding clinical side effects from non-selective inhibitors.

Selective PDE7 inhibitors boost cAMP levels to enhance dopamine signaling, reducing levodopa doses and delaying dyskinesia onset.

Excipient segmentation reduces teratogenic exposure risks while improving bioavailability of substituted diaminopurine.

Antibodies bind CD73 epitopes to neutralize ecto-5 nucleotidase activity.

Fusion proteins with J domains and binding segments target alpha-synuclein aggregates, reducing cytotoxicity without addressing underlying disease progression.

Allele-specific primers hybridize to nucleic acid molecules encoding GPR156 variants through complementary base pairing.

Ultra low dose doxepin treats insomnia while avoiding tolerance and addiction potential of traditional hypnotics.

An antibody-toxin conjugate delivers cytotoxic agents to HER2-positive tumor cells.

CAQK peptides bind to brain injury lesions, overcoming blood-brain barrier limits to improve drug retention at acute trauma sites.

2'-fluoro-modified RNA aptamers resist ribonuclease degradation in biological fluids while maintaining nano- to micromolar potency against AMPA receptors.

Segmented antibody design resolves therapeutic effectiveness versus targeting capability in TTR amyloidosis treatment.

Gamma-secretase cleaves EphA4 polypeptides to activate Rac and promote spine formation, addressing the lack of knowledge about this processing pathway.

Segmented antibodies target the Asp421 Tau epitope, resolving specificity and sensitivity limits in early Alzheimer's diagnosis.

18F-labeled normemantine derivative targets NMDA receptors via positron emission tomography.

Combining PM01183 with platinum coordination complexes overcomes drug resistance while reducing toxicity in advanced metastatic cancers.

Novel benzamide derivatives target 5-HT4 receptors with high binding affinity, reducing gastric emptying time while minimizing adverse side effects.

Adjusting doxepin administration with or without food resolves the trade-off between rapid onset and high bioavailability.

A C. elegans locomotor model mimics early alpha-synuclein-mediated neurodegeneration to identify repurposed therapeutics like rifabutin and losartan.

Peptide epitopes activate T cells to attack pancreatic cancer, bypassing chemotherapeutic resistance in the dense stroma.

Tricyclic kinase inhibitors resolve selectivity trade-offs by targeting JAK2 and CDK11, inducing apoptosis in cancer cells.

Administering a fenfluramine 5-HT4 agonist stimulates brainstem receptors, preventing fatal respiratory arrest in patients receiving opioids.

Compounds reduce TDP-43 toxicity and aggregation while preserving normal expression levels, addressing safety gaps in ALS treatments.

Bispecific binding molecules combine target recognition with proteasome stimulation to enhance protein degradation efficiency in neurodegenerative diseases.